SCHEMBL2118332

SCHEMBL2118332

COc1ccc(N(C(C)c2ccc(Cl)cc2)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 5/20 0.53
PSEN2 P49810 5/20 0.53
APH1B Q8WW43 5/20 0.53
NCSTN Q92542 5/20 0.53
APH1A Q96BI3 5/20 0.53
PSENEN Q9NZ42 5/20 0.53
ALDH1A1 P00352 2/20 0.53
USP2 O75604 1/20 0.53
TP53 P04637 3/20 0.48
PGR P06401 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MDM4 O15151 1/20 0.46
MDM2 Q00987 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
OXTR P30559 1/20 0.44
AVPR1A P37288 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116723 0.78 PSEN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL10558324 0.78 CYP3A4 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5622693 0.75 ESR1 (0.54) ALDH1A1USP2TP53PGRL3MBTL1
SCHEMBL2120197 0.75 TP53 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL16373314 0.72 SLC2A1 (0.50) ALDH1A1USP2L3MBTL1TSHRMAPK1
SCHEMBL10560203 0.72 CYP19A1 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL28134996 0.72 L3MBTL1 (0.61) ALDH1A1PGRL3MBTL1MAPTTSHR
SCHEMBL2118315 0.72 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2119170 0.71 PSEN1 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6534675 0.71 PGR (0.71) ALDH1A1USP2TP53PGRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 PSEN1 2194/4885PSEN2 1942/4885APH1B 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.